PAVmed to Join Russell Microcap® Index
June 22 2017 - 4:01PM
Business Wire
PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly
differentiated, multiproduct medical device company, today
announced that the Company will join the Russell Microcap® Index at
the conclusion of the Russell Indexes’ annual reconstitution,
effective after the U.S. market opens on June 26, 2017, according
to a preliminary list of additions posted June 9, 2017 and again on
June 16, 2017.
Membership in the Russell Microcap® Index provides automatic
inclusion in the appropriate market indexes. FTSE Russell
determines membership for its Russell indexes primarily by
objective, market-capitalization rankings and style attributes.
“We are pleased that PAVmed will now be included in the Russell
Microcap® Index,” said Lishan Aklog, M.D., PAVmed’s Chairman and
Chief Executive Officer. “We expect it will raise our visibility
within the investment community as we continue our drive to enhance
shareholder value.”
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Russell indexes are part of FTSE
Russell, a leading global index provider.
For more information on the Russell Microcap® Index and the
Russell indexes reconstitution, go to the “Russell Reconstitution”
section on the FTSE Russell website.
About FTSE Russell
FTSE Russell is a leading global index provider creating and
managing a wide range of indexes, data and analytic solutions to
meet client needs across asset classes, style and strategies.
Covering 98% of the investable market, FTSE Russell indexes offer a
true picture of global markets, combined with the specialist
knowledge gained from developing local benchmarks around the
world.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. More than $12.5
trillion is currently benchmarked to FTSE Russell indexes. For over
30 years, leading asset owners, asset managers, ETF providers and
investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create investment funds, ETFs,
structured products and index-based derivatives. FTSE Russell
indexes also provide clients with tools for asset allocation,
investment strategy analysis and risk management.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on index innovation and customer
partnership applying the highest industry standards and embracing
the IOSCO Principles. FTSE Russell is wholly owned by London Stock
Exchange Group. For more information, visit ftserussell.com.
About PAVmed
PAVmed Inc. is a highly differentiated, multiproduct medical
device company employing a unique business model designed to
advance products from concept to commercialization much more
rapidly and with significantly less capital than the typical
medical device company. This proprietary model enables PAVmed to
pursue an expanding pipeline strategy with a view to enhancing and
accelerating value creation. PAVmed’s diversified pipeline of
products address unmet clinical needs, have attractive regulatory
pathways and market opportunities and encompass a broad spectrum of
clinical areas including carpal tunnel syndrome (CarpX™), medical
infusions (NextFlo™ and NextCath™), interventional radiology
(PortIO™ and NextCath™), tissue ablation and cardiovascular
intervention (Caldus™) and pediatric ear infections (DisappEAR™).
The Company intends to further expand its pipeline through
engagements with clinician innovators and leading academic medical
centers. For further information, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements, based upon the current beliefs and expectations of the
Company’s management, are subject to risks and uncertainties, which
could cause actual results to differ from the forward-looking
statements. Risks and uncertainties that may cause such differences
include, among other things, the uncertainties inherent in research
and development, including the cost and time required advance our
products to regulatory submission; whether regulatory authorities
will be satisfied with the design of and results from our
preclinical studies; whether and when our products are cleared by
regulatory authorities; market acceptance of our products once
cleared and commercialized; our ability to raise additional funding
and other competitive developments. PAVmed has not yet received
clearance from the FDA or other regulatory body to market any of
its products. New risks and uncertainties may arise from time to
time and are difficult to predict. All of these factors are
difficult or impossible to predict accurately and many of them are
beyond our control. For a further list and description of these and
other important risks and uncertainties that may affect our future
operations, see Part I, Item IA, “Risk Factors,” in our most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission, as the same may be updated in Part II, Item 1A, “Risk
Factors” in any Quarterly Reports on Form 10-Q filed by us after
our most recent Annual Report. We disclaim any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in our expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170622006105/en/
InvestorsLHA Investor RelationsKim
Sutton Golodetz(212) 838-3777kgolodetz@lhai.comorMediaRooneyPartnersKate Barrette(212)
223-0561Kbarrette@rooneyco.com
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Mar 2024 to Apr 2024
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Apr 2023 to Apr 2024